Latest news

• Celgene’s Revlimid scores NICE approval in follicular lymphoma

  lymphoma. Follicular lymphoma is the most common type of low-grade non-Hodgkin’s lymphoma, and despite having a median overall survival rate of over 15 years, patients are prone to ... Lenalidomide is a new type of targeted cancer therapy for people

• EU grants conditional approval to Roche's lymphoma drug Polivy

  The EU approval clears Polivy for use in combination with chemotherapy drug bendamustine and anti-CD20 rituximab in adults with relapsed/refractory  diffuse large B-cell lymphoma (DLBCL) who are ineligible ... Filings for approval in first-line DLBCL

• Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

  This includes trials of tafasitamab in non-Hodgkins lymphoma, chronic lymphocytic leukaemia (CLL), relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) and frontline DLBCL. ... beyond DLBCL, such as follicular lymphoma (FL), marginal zone

• AstraZeneca’s Calquence impresses in previously untreated CLL

  However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy  Brukinsa (zanubrutinib). ... It is also in clinical development for a host of other blood

• AstraZeneca wins FDA approval for Calquence in chronic lymphoma

  and small lymphocytic lymphoma (SLL), taking the fight to AbbVie/Johnson &Johnson’s Imbruvica. . ... The Chinese drugmaker's therapy is also in clinical development for CLL, SLL, follicular lymphoma and marginal zone lymphoma.